AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06461195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring of patients
Description: Data from a spirometer and a stethoscope are captured to develop algorithms to detect and classify respiration sounds to support therapists and patients in future therapy.
Study NCT06154759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watson Human Caring Model-based psychoeducation
Description: It is a psychoeducation program based on the Watson human care model, one of the theories of the nursing profession, that includes healing processes, and consists of sessions that address the hopelessness, death anxiety and care burden of individuals.
Study NCT06699680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX019
Description: Specified dose on specified days
Study NCT06699680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT06698874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ds-MCE and EGD examinations
Description: Sequentially performing ds-MCE and EGD examinations on enrolled participants.
Study NCT06699654 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: A gel without active Spirulina components applied as a control intervention.
Study NCT06699654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spirulina Gel
Description: A conventional Spirulina gel formulation applied as a periodontal therapy.
Study NCT06699654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina Nanoparticles Gel
Description: A novel Spirulina nanoparticles gel formulation applied as a periodontal therapy.
Study NCT06700317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HSS1
Description: Surgery performed using HSS1
Study NCT06698588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Fish Oil supplements
Description: Wileys Easy Swallow Mini Softgel capsules, dose 3 caps/day, providing 945mg/day long-chain omega-3 (540mg EPA, 405mg DHA).
Study NCT06698588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: high-oleic sunflower oil (which broadly matches the overall fatty acid composition of typical UK diet), matched with active treatment for appearance and taste.
Study NCT05270265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pvs25-IMX313/Matrix-M1
Description: Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
Study NCT06415591 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous electrical nerve field stimulation
Description: FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
Study NCT06415591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous electrical nerve field stimulation
Description: FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
Study NCT05996627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Given PO
Study NCT06125236 — intervention group
Intervention type: OTHER
Intervention: Visit at D90
Description: Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
Study NCT05142917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
Study NCT05142917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
Study NCT05142917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand motor task
Description: Various type of hand motor tasks are applied to stroke patients.
Study NCT05485376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Artery Catheter
Description: The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.
Study NCT05996627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05996627 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05996627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary study
Study NCT05996627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary study
Study NCT05996627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT06532097 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical and behavioral smartwatch-based activation
Description: We used smartwatches to provide an interactive tool for delivering a mixed intervention of physical and behavioral activation, with the former addressing physical activity level and the latter pleasant activities including and beyond physical activity (e.g., social, relaxing activities). Moreover, given the relationship with physical activity level, we additionally incorporated digital insomnia exercises that have also shown large effects in the amelioration of depression.
Study NCT06451952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual darkness
Description: Chronotheraphy
Study NCT05878288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cemiplimab
Description: Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
Study NCT05721105 — intervention group
Intervention type: OTHER
Intervention: Quality of life assessment using questionnaires
Description: Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
Study NCT06497010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: PD-1
Description: Intravenous (IV) infusion
Study NCT06497010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: InnoPCV
Description: Intramuscular (IM) injection
Study NCT04637763 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CB-010
Description: CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
Study NCT04637763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study NCT04637763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion
Study NCT05192044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast track Care pancreatico-duodenectomy.
Description: Enhanced recovery after pancreatico-duodenectomy, with early oral intake, mobilization \& discharge
Study NCT05192044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Conventional Care
Study NCT03643198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)
Description: The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
Study NCT03643198 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CONTROL
Description: NO treatment
Study NCT03643198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: NO treatment
Study NCT04691531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The use of classical Gauge 22 needle
Description: After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
Study NCT04691531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The use of classical Gauge 27 needle
Description: After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
Study NCT05028478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN202
Description: Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
Study NCT06275464 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BT-600
Description: NaviCap device containing liquid formulation of Tofacitinib
Study NCT05142917 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hand motor task
Description: Various type of hand motor tasks are applied to stroke patients.
Study NCT05142917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand motor task
Description: Various type of hand motor tasks are applied to stroke patients.
Study NCT04452305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting
Description: Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
Study NCT06275464 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: BT-600 Placebo
Description: NaviCap device containing placebo formulation
Study NCT06091449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fidelity simulation
Description: Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).
Study NCT06357429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Cold application was applied to the LI4 acupressure point on the patients' hands using an ice battery.
Study NCT04882124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
Study NCT06091449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: For the virtual reality-based simulation application, students can log in to the virtual reality-based simulation program prepared in line with the Diabetes Mellitus scenario using their username and password; They will receive modular training integrated into the simulation. The expected time for students to complete the modular training is 30 minutes. Students who complete the module will be asked to take a 10-minute break and then participate in a virtual reality-based simulation application.The application of high-fidelity simulation is the same in both groups.
Study NCT04882124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
Study NCT04904640 — intervention group
Intervention type: DEVICE
Intervention: Hip stem
Description: In every hip (with appropriate CT scan), 3 different stem designs will be positioned using a 3D Ct based software for surgical pre-operative planning.
Study NCT03659708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lyon-VTE score
Description: follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
Study NCT03659708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recommendations currently available
Description: follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
Study NCT04886505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolytic eCLIPs Bifurcation System
Description: The electrolytic eCLIPs bifurcation system will be implanted into patients with bifurcated saccular intra-cranial aneurysms.
Study NCT05689671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg i.v. q3w
Study NCT05689671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 100 mg/m² i.v. qw
Study NCT05689671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 i.v. q3w
Study NCT05689671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg i.v. q3w
Study NCT05689671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m² i.v. q3w
Study NCT05689671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5-6 i.v. q3w
Study NCT05689671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m² i.v. q3w
Study NCT06269185 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
Study NCT06269185 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
Study NCT04481204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT04481204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT04481204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT04481204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Given IV
Study NCT04481204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Given IV
Study NCT04481204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT04481204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT04481204 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT06186895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
Study NCT06186895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
Study NCT01345422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Balance Board
Description: Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
Study NCT06646172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse thoracic muscle plane block (TTMPB) using liposomal bupivacaine and bupivacaine mixture
Description: Liposomal bupivacaine and bupivacaine mixture were used for transverse thoracic muscle plane block (TTMPB) in experimental group.
Study NCT06646172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse thoracic muscle plane block (TTMPB) using bupivacaine hydrochloride
Description: Bupivacaine hydrochloride was used for transverse thoracic muscle plane block (TTMPB) in active control group.
Study NCT04885075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV diazepam
Description: inj.diazepam 0.2mg/kg/dose stat
Study NCT04885075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: I/N Midazolam
Description: intranasal midazolam 0.2mg/kg/dose stat
Study NCT05420961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Study NCT05126550 — intervention group
Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccine (Vero cell) inactivated
Description: Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)
Study NCT05868460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity laser
Description: patients will receive Nd: YAG with wavelength 1064 nm, peak power 3KW, energy density 360-1780 mJ/cm2, a short duration 120-150 micro sec, a mean power 10.5 W, a low frequency 10-40 HZ, a duty cycle of 0.1%, a probe diameter of 0.5 cm and spot size of 0.2 cm2. The treatment will be applied into 3 phases in each session. In addition to the traditional physical therapy exercise program (passive and active ROM exercises, stretching and strengthening exercises) for 20 minutes, total session time is 35 minutes, 3 days/ week for 4 weeks.
Study NCT05868460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy exercise program
Description: passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.
Study NCT05868460 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional physical therapy exercise program
Description: passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.
Study NCT05868460 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo High intensity laser
Description: patients will receive placebo HILT including the same treatment as in group A but the laser device will be turned off.
Study NCT05420961 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV15
Description: Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
Study NCT05420961 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Study NCT05366179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.B7-H3T cells infusion
Description: The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2).
Study NCT05959577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled hemorrhoidopexy with anoplasty
Description: The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.
Study NCT05959577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ferguson hemorrhoidectomy
Description: Ferguson hemorrhoidectomy
Study NCT06210659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Theory of Planned Behavior Based Training Program
Description: Theory of Planned Behavior Based Training Program will be implemented. The training program will consist of 4 sessions. First session; It will consist of the definition, symptoms and treatment approaches of primary dysmenorrhea. Content of the second session; It will consist of lifestyle interventions in dysmenorrhea. Content of the third session; It will consist of the importance of physical activity in primary dysmenorrhea. The fourth session consists of a group walk.~Students will be monitored for 3 menstrual cycles. Starting from the end of the first menstrual period after completion of the training session, students will be asked to record their daily step count using a pedometer. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated. After the training sessions are completed, students will be given an end-of-menstrual motivational interview for 3 menstrual cycles.